MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "Parkinson’s"

  • 2024 International Congress

    Evaluation of Infusion Site Adverse Events With Foslevodopa/Foscarbidopa in a 12-Week, Randomized Study

    S. Isaacson, R. Kirsner, O. Vaou, R. Pahwa, R. Hauser, L. Bergmann, R. Gupta, M. Shah, S. Varughese, T. Kimber (Boca Raton, USA)

    Objective: To characterize infusion site events (ISEs) in patients with advanced Parkinson’s disease (aPD) treated with foslevodopa/foscarbidopa (LDp/CDp). Background: ISEs, including local reactions and infusion…
  • 2024 International Congress

    Remotely-deployed gamification intervention to increase physical activity in Parkinson’s Disease

    K. Waddell, M. Smith, S. Wood, R. Greysen, J. Morley (Philadelphia, USA)

    Objective: To describe a remote, behavioral intervention designed to increase daily steps in Veterans with PD and report interim results from an ongoing clinical trial…
  • 2024 International Congress

    Neurocognitive Functioning (NF) in a Patient with Idiopathic Parkinson’s Disease without Dementia (IPDWD). Subjected to Deep Brain Stimulation (DBS) and Treatment by Clinical, Functional and Advanced Neuropsychology.

    C A. Hurtado-Gonzalez, J F. Ayala-Rico, S. Ospina-Otalvaro, P A. Lenis, J M. Márquez, C O. Moreno, M. Agudelo, S. Guerrero (Cali, Colombia)

    Objective: To identify the Neurocognitive Functioning (NF) in a patient with IPDWD and intervened by DBS, and to analyze the impact of functional neurorehabilitation (FNR)…
  • 2024 International Congress

    Effects of ATH434, a Clinical-Phase Small Molecule with Moderate Affinity for Iron, in a Parkinson’s Disease Model in Macaques

    M. Bradbury, M. Aumann, D. Claassen, D. Finkelstein (Newark, USA)

    Objective: (1) Determine whether oral ATH434 improves motor performance in a non-human primate hemiparkinasonian model when administered after symptom onset. (2) Relate observations to changes…
  • 2024 International Congress

    Baseline Variables Associated with Apomorphine Sublingual Film Retention

    J. Kassubek, J. Schwarz, L. López Manzanares, M. Fonseca, C. Denecke Muhr (Ulm, Germany)

    Objective: The aim of this analysis was to identify the baseline variables that differ between patients who completed Study CTH-301 and those who discontinued during…
  • 2024 International Congress

    Moderators of aerobic exercise effects on motor symptoms in patients with Parkinson’s disease: a systematic review and meta-analysis

    R. Kim, N. Kang (Seoul, Republic of Korea)

    Objective: To investigate the difference in the effects of aerobic exercise on motor function in patients with Parkinson's disease (PD) according to exercise intervention protocols.…
  • 2024 International Congress

    Long term evaluation of gluten-free diet in Parkinson´s disease patients

    H. Brožová, K. Poláková, T. Gentileová, M. Fialová, M. Kubjatková, J. Rusz, M. Sap, M. Kuzma, H. Pelantová, M. Jandová, D. Funda (Prague, Czech Republic)

    Objective: The primary aim of the project was to evaluate the effect of long-term administered gluten-free diet (GFD) on motor symptoms of Parkinson's disease (PD).…
  • 2024 International Congress

    Identifying the Most Sensitive Patient-reported Items from the MDS-UPDRS that Predict Initiation of PD Medications in Early Disease

    H. Zou, C. Goetz, G. Stebbins, T. Mestre, S. Luo (Durham, USA)

    Objective: Objective: To determine the most sensitive combination of MDS-UPDRS Parts IB and II items that accurately predicted the clinically relevant target of dopaminergic therapy…
  • 2024 International Congress

    Role of RNA splicing in Parkinson’s disease

    K. Irmady, C. Hale, R. Qadri, J. Fak, T. Carroll, R. Darnell (New York, USA)

    Objective: To identify key molecular perturbations affecting medium spiny neuron functions and their role in the clinical symptoms of Parkinson’s disease (PD). Background: The degeneration…
  • 2024 International Congress

    Serum levels of VEGF-C and ENDGLIN in Parkinson’s disease and their clinical relevance

    S. Haji, W. Sako, Y. Osaki, Y. Izumi (Tokushima, Japan)

    Objective: To evaluate the differences in serum concentrations of neurovascular unit (NVU)-related cytokines between patients with Parkinson's disease (PD) and control subjects (Ctr) and to…
  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • …
  • 338
  • Next Page »

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • #25676 (not found)
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
    • Effect of marijuana on Essential Tremor: A case report
    • Estimation of the 2020 Global Population of Parkinson’s Disease (PD)
    • Help & Support
    • About Us
    • Cookies & Privacy
    • Wiley Job Network
    • Terms & Conditions
    • Advertisers & Agents
    Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
    Wiley